Artificial intelligence discovers a new inhibitor targeting macrophage-myofibroblast transition, suggesting a novel treatment for chronic kidney disease.
Chronic kidney disease (CKD) is a leading global cause of mortality, often linked with non-communicable diseases such as diabetes, cardiovascular disease, and cancer. Effective treatments to halt kidney fibrosis remain lacking. Macrophage–Myofibroblast Transition (MMT) is a critical driver of CKD progression. This study aimed to develop a novel therapeutic strategy targeting MMT by inhibiting its key regulator, the neuronal transcription factor Pou4f1.
No takes yet. Share an insight, caveat, or question.
Chung et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: